Retatrutide — Clinical Biochemistry

Biochemistry · Basic Sciences

How it begins

Análisis exhaustivo de la bioquímica clínica del primer agonista triple de los receptores GIP, GLP-1 y glucagón: mecanismos moleculares de señalización, efectos metabólicos multi-órgano, farmacocinética, evidencia clínica y perspectivas terapéuticas.

What it covers

1. Overview of Obesity and the Hormone Agonist Revolution
2. · Evolution of Hormone Agonists for Obesity
3. The Incretin System: Essential Biochemistry
4. · GLP-1 (Glucagon-Like Peptide Type 1)
5. · GIP (Gastric Inhibitory Peptide / Glucose Dependent Insulinotropic Peptide)
6. · Glucagon
7. · The Incretin Effect and its Dysfunction in Obesity and T2DM
8. Molecular Structure of Retatrutide
9. · Design Based on the GIP Skeleton
10. · Modifications that Grant Stability and Prolonged Half-Life
11. · Target Receivers: Structure and Family
12. GLP-1R Agonism: Molecular Signaling Cascade
13. · The GLP-1 Receptor (GLP-1R): Expression and Structure
14. · GLP-1R Signaling Cascade: Pancreatic β Cell
15. · GLP-1R Signaling in the CNS: Anorexia and Satiety
16. · β-Arrestin and Biased Signaling of GLP-1R
17. GIPR Agonism: Signaling and the GIP Paradox Resolved
18. · The GIP Receptor (GIPR): Tissue Expression and Paradox
19. · GIPR Signaling Cascade
20. · GIPR in the Bone: Anabolic Effect
21. GcgR Agonism: Beyond Hyperglycemia
22. · The Glucagon Receptor (GcgR): Rediscovered
23. · GcgR Signaling in the Liver: Beneficial Metabolic Effects
24. · GcgR and Energy Expenditure: The Retatrutide Differentiator
25. The Synergy of Triple Agonism: Molecular Balance and Emergence
26. · Demonstrated or Proposed Synergies
27. · Key Molecular Circuits Activated by Triple Agonism
28. Pancreas: Effects on the β, α and δ Cell
29. · Effects on the β Cell (Insulinotrophic + Trophic)
30. · Effects on the α Cell: Regulation of Endogenous Glucagon
31. · Effects on the δ Cell: Somatostatin
32. · Controversy: Risk of Pancreatitis and Pancreatic Carcinoma?
33. Adipose Tissue: Lipolysis, Thermogenesis and Remodeling
34. · White Adipose Tissue (WAT): Lipolysis and Fat Mass Reduction
35. · Brown Adipose Tissue (BAT) and Beige: Thermogenesis Without Coupling
36. · Adipocins: Restoration of the Secretory Profile
37. Liver: MASLD/MASH and Hepatic Lipid Metabolism
38. · Pathophysiology of MASLD and Targets of Retatrutide
39. · Preclinical and Clinical Data of Retatrutide in MASH
40. Central Nervous System: Regulation of Appetite and Energy Homeostasis
41. · The Hypothalamus as an Integrator of the Energy Balance
42. · Mechanisms of Anorexia Induced by Retatrutide
43. · Possible Neuroprotective Effects: Alzheimer's and Parkinson's
44. Skeletal Muscle: Preservation of Lean Mass and Oxidative Metabolism
45. · The Challenge of Muscle Preservation in Weight Loss
46. · Mechanisms of Action in Skeletal Muscle
47. Cardiovascular and Renal Effects of Retatrutide
48. · Cardioprotective Effects of GLP-1R Agonism
49. · The TRIUMPH-CVOT Trial: Perspective of Retatrutide
50. · Kidney Effects
51. · Lipid Profile
52. Pharmacokinetics and Pharmacodynamics
53. · Pharmacokinetics: LADME of Retatrutide
54. · Pharmacodynamics: Dose-Response Relationship
55. · Dose Escalation: Titration Protocol
56. Clinical Trials: Phase 2 and the TRIUMPH Program
57. · Phase 2 Trial: NCT04881760
58. · Type 2 Diabetes Trial (Phase 2)
59. · TRIUMPH Program: Phase 3 Trials
60. Biochemical Comparison: Retatrutide vs. Semaglutide vs. Tirzepatide
61. · Compared Pharmacological Profiles
62. · Comparative Weight Reduction: Visualization
63. · What does GcgR Contribute to Dual Agonism?
64. Safety Profile and Adverse Effects
65. · Gastrointestinal Adverse Effects: The Achilles Heel
66. · Reactions at the Injection Site
67. · Tachycardia
68. · Contraindications
69. · Drug Interactions
70. Future Indications, Perspectives and Future Biochemistry
71. · Emerging Indications in Clinical Development
72. · The Horizon: Beyond Triple Agonism
73. · Biochemical Summary Table: Retatrutide at a Glance